Juanita M Crook1, Chad Tang2, Howard Thames3, Pierre Blanchard3, Jeremiah Sanders4, Jay Ciezki5, Mira Keyes6, W James Morris7, Gregory Merrick8, Charles Catton9, Hamid Raziee10, Richard Stock11, Frank Sullivan12, Mitch Anscher3, Jeremy Millar13, Steven Frank14. 1. BC Cancer, University of British Columbia, Kelowna, Canada. Electronic address: jcrook@bccancer.bc.ca. 2. MD Anderson Cancer Center, University of Texas, Houston, United States. Electronic address: CTang1@mdanderson.org. 3. MD Anderson Cancer Center, University of Texas, Houston, United States. 4. MD Anderson Cancer Center, University of Texas, Houston, United States. Electronic address: JSanders1@mdanderson.org. 5. Cleveland Clinic, Case Western Reserve University, Cleveland, United States. Electronic address: CIEZKIJ@ccf.org. 6. BC Cancer, University of British Columbia, Vancouver, Canada. Electronic address: mkeyes@bccancer.bc.ca. 7. BC Cancer, University of British Columbia, Vancouver, Canada. 8. Schiffler Cancer Center, Wheeling, United States. Electronic address: GMerrick@urologicresearchinstitute.org. 9. University Health Network, University of Toronto, Canada. Electronic address: Charles.Catton@rmp.uhn.ca. 10. University Health Network, University of Toronto, Canada. Electronic address: hamid.raziee@bccancer.bc.ca. 11. Mt Sinai School of Medicine, NY, United States. Electronic address: richard.stock@mountsinai.org. 12. National University of Ireland, Galway, Ireland. Electronic address: f.sullivan@me.com. 13. Alfred Health, Melbourne Australia. Electronic address: jeremy.millar@monash.edu. 14. MD Anderson Cancer Center, University of Texas, Houston, United States. Electronic address: sjfrank@mdanderson.org.
Abstract
BACKGROUND AND PURPOSE: To identify a PSA threshold value at an intermediate follow-up time after low dose rate (LDR) prostate brachytherapy associated with cure, defined as long-term (10-15 year) freedom from prostate cancer. MATERIALS AND METHODS: Data from 7 institutions for 14,220 patients with localized prostate cancer treated with LDR brachytherapy, either alone (8552) or with external beam radiotherapy (n = 1175), androgen deprivation (n = 3165), or both (n = 1328), were analyzed. Risk distribution was 42.4% favorable, 49.2% intermediate, and 8.4% high-risk. Patients with clinical failure before 3.5 years were excluded. Kaplan-Meier analysis was used with clinical failure (local, distant, regional or biochemical triggering salvage) as an endpoint for each of four PSA categories: PSA ≤ 0.2, >0.2 to ≤0.5, >0.5 to ≤1.0, and >1.0 ng/mL. PSA levels at 4 years (±6 months) in 8746 patients without clinical failure were correlated with disease status at 10-15 years. RESULTS: For the 77.1% of patients with 4-year PSA ≤ 0.2, the freedom-from-recurrence (FFR) rates were 98.7% (95% CI 98.3-99.0) at 10 years and 96.1% (95% CI 94.8-97.2) at 15 years. Three independent validation cohorts confirmed 97-99% 10-year FFR rates with 4-year PSA ≤ 0.2. Successive PSA categories were associated with diminished disease-free rates at 10 and 15 years. PSA category was strongly associated with treatment success (p < 0.0005). CONCLUSIONS: Since 98.7% of patients with PSA ≤ 0.2 ng/mL at 4 years after LDR prostate brachytherapy were disease-free beyond 10 years, we suggest adopting this biochemical definition of cure for patients with ≥4 years' follow-up after LDR brachytherapy.
BACKGROUND AND PURPOSE: To identify a PSA threshold value at an intermediate follow-up time after low dose rate (LDR) prostate brachytherapy associated with cure, defined as long-term (10-15 year) freedom from prostate cancer. MATERIALS AND METHODS: Data from 7 institutions for 14,220 patients with localized prostate cancer treated with LDR brachytherapy, either alone (8552) or with external beam radiotherapy (n = 1175), androgen deprivation (n = 3165), or both (n = 1328), were analyzed. Risk distribution was 42.4% favorable, 49.2% intermediate, and 8.4% high-risk. Patients with clinical failure before 3.5 years were excluded. Kaplan-Meier analysis was used with clinical failure (local, distant, regional or biochemical triggering salvage) as an endpoint for each of four PSA categories: PSA ≤ 0.2, >0.2 to ≤0.5, >0.5 to ≤1.0, and >1.0 ng/mL. PSA levels at 4 years (±6 months) in 8746 patients without clinical failure were correlated with disease status at 10-15 years. RESULTS: For the 77.1% of patients with 4-year PSA ≤ 0.2, the freedom-from-recurrence (FFR) rates were 98.7% (95% CI 98.3-99.0) at 10 years and 96.1% (95% CI 94.8-97.2) at 15 years. Three independent validation cohorts confirmed 97-99% 10-year FFR rates with 4-year PSA ≤ 0.2. Successive PSA categories were associated with diminished disease-free rates at 10 and 15 years. PSA category was strongly associated with treatment success (p < 0.0005). CONCLUSIONS: Since 98.7% of patients with PSA ≤ 0.2 ng/mL at 4 years after LDR prostate brachytherapy were disease-free beyond 10 years, we suggest adopting this biochemical definition of cure for patients with ≥4 years' follow-up after LDR brachytherapy.
Authors: W James Morris; Scott Tyldesley; Sree Rodda; Ross Halperin; Howard Pai; Michael McKenzie; Graeme Duncan; Gerard Morton; Jeremy Hamm; Nevin Murray Journal: Int J Radiat Oncol Biol Phys Date: 2016-11-24 Impact factor: 7.038
Authors: Mack Roach; Gerald Hanks; Howard Thames; Paul Schellhammer; William U Shipley; Gerald H Sokol; Howard Sandler Journal: Int J Radiat Oncol Biol Phys Date: 2006-07-15 Impact factor: 7.038
Authors: Emmanuel S Antonarakis; Yongmei Chen; Sally I Elsamanoudi; Stephen A Brassell; Mario V Da Rocha; Mario A Eisenberger; David G McLeod Journal: BJU Int Date: 2010-11-23 Impact factor: 5.588
Authors: Andrea C Lo; W James Morris; Vincent Lapointe; Jeremy Hamm; Mira Keyes; Tom Pickles; Michael McKenzie; Ingrid Spadinger Journal: Int J Radiat Oncol Biol Phys Date: 2014-01-01 Impact factor: 7.038
Authors: F A Critz; W H Williams; C T Holladay; A K Levinson; J B Benton; D A Holladay; F J Schnell; L S Maxa; P D Shrake Journal: Urology Date: 1999-12 Impact factor: 2.649
Authors: Thomas Van den Broeck; Roderick C N van den Bergh; Erik Briers; Philip Cornford; Marcus Cumberbatch; Derya Tilki; Maria De Santis; Stefano Fanti; Nicola Fossati; Silke Gillessen; Jeremy P Grummet; Ann M Henry; Michael Lardas; Matthew Liew; Malcolm Mason; Lisa Moris; Ivo G Schoots; Theodorus van der Kwast; Henk van der Poel; Thomas Wiegel; Peter-Paul M Willemse; Olivier Rouvière; Thomas B Lam; Nicolas Mottet Journal: Eur Urol Focus Date: 2019-06-24
Authors: Rebecca G Levin-Epstein; Naomi Y Jiang; Xiaoyan Wang; Shrinivasa K Upadhyaya; Sean P Collins; Simeng Suy; Nima Aghdam; Constantine Mantz; Alan J Katz; Leszek Miszczyk; Aleksandra Napieralska; Agnieszka Namysl-Kaletka; Nicholas Prionas; Hilary Bagshaw; Mark K Buyyounouski; Minsong Cao; Nzhde Agazaryan; Audrey Dang; Ye Yuan; Patrick A Kupelian; Nicholas G Zaorsky; Daniel E Spratt; Osama Mohamad; Felix Y Feng; Brandon A Mahal; Paul C Boutros; Arun U Kishan; Jesus Juarez; David Shabsovich; Tommy Jiang; Sartajdeep Kahlon; Ankur Patel; Jay Patel; Nicholas G Nickols; Michael L Steinberg; Donald B Fuller; Amar U Kishan Journal: Radiother Oncol Date: 2020-10-07 Impact factor: 6.280
Authors: Jeremiah W Sanders; Rajat J Kudchadker; Chad Tang; Henry Mok; Aradhana M Venkatesan; Howard D Thames; Steven J Frank Journal: Radiol Artif Intell Date: 2022-01-26
Authors: Jennifer Uribe; Santiago Uribe-Lewis; Sara Khaksar; Carla Perna; Christos Mikropoulos; Sophie Otter; Robert Laing; Stephen Langley Journal: BJUI Compass Date: 2020-10-19
Authors: Esther Mayrata; Jose Maria Espinosa; David Büchser; Francisco Casquero; Fernan Suárez; Alba González; Pablo Minguez; Jose Fernando Pérez; Iñigo San Miguel; Jon Cacicedo; Alfonso Gómez-Iturriaga Journal: J Contemp Brachytherapy Date: 2021-02-18
Authors: Jose Luis Guinot; Juan Casanova; Victor Gonzalez-Perez; Miguel Angel Santos; Victor De Los Dolores; Maria Isabel Tortajada; Carmen Guardino; Vicente Crispin; Jose Rubio-Briones; Leoncio Arribas Journal: J Contemp Brachytherapy Date: 2022-05-12